Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Jun;72(6):767–771. doi: 10.1136/jnnp.72.6.767

Anti-GT1a IgG in Guillain-Barré syndrome

M Koga 1, H Yoshino 1, M Morimatsu 1, N Yuki 1
PMCID: PMC1737908  PMID: 12023422

Abstract

Objective: To investigate the presence of serum anti-GT1a IgG in Guillain-Barré syndrome (GBS) and its relation to clinical manifestations.

Background: Several patients with GBS and bulbar palsy have been reported to have serum anti-GT1a IgG. Most, however, also have anti-GQ1b IgG. A previous study failed to detect GT1a in human cranial nerves, but GQ1b was abundant in human ocular motor nerves. Whether anti-GT1a IgG itself determines the clinical manifestations is not yet clear.

Methods: The association of clinical manifestations with the presence of anti-GT1a IgG and with its cross reactivity was investigated. An immunochemical study was performed to determine whether GT1a is present in human cranial nerves.

Results: Anti-GT1a and anti-GQ1b IgG were positive in 10% and 9% respectively of 220 consecutive patients with GBS. Patients with anti-GT1a IgG often had cranial nerve palsy (ophthalmoparesis, 57%; facial palsy, 57%; bulbar palsy, 70%), and 39% needed artificial ventilation. These features were also seen in patients with anti-GQ1b IgG. There was no significant difference between the two groups with respect to the frequency of clinical findings. An enzyme-linked immunosorbent assay showed that anti-GT1a IgG cross reacted with GQ1b in 75% of the patients, GD1a in 30%, GM1 in 20%, and GD1b in 20%. All five patients who carried anti-GT1a IgG that did not cross react with GQ1b had bulbar palsy, neck weakness, absence of sensory disturbance, and positive Campylobacter jejuni serology. Thin-layer chromatography with immunostaining showed that GT1a is present in human oculomotor and lower cranial nerves.

Conclusions: These findings provide further evidence that anti-GT1a IgG itself can determine clinical manifestations. The distinctive clinical features of patients with anti-GT1a IgG without anti-GQ1b activity distinguish a specific subgroup within GBS.

Full Text

The Full Text of this article is available as a PDF (130.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando S., Yu R. K. Isolation and characterization of a novel trisialoganglioside, GT1a, from human brain. J Biol Chem. 1977 Sep 25;252(18):6247–6250. [PubMed] [Google Scholar]
  2. Asbury A. K., Cornblath D. R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 (Suppl):S21–S24. doi: 10.1002/ana.410270707. [DOI] [PubMed] [Google Scholar]
  3. Aspinall G. O., McDonald A. G., Pang H., Kurjanczyk L. A., Penner J. L. Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry. 1994 Jan 11;33(1):241–249. doi: 10.1021/bi00167a032. [DOI] [PubMed] [Google Scholar]
  4. Bandou N., Ise M., Akita H., Kozan H., Sekiguchi T., Ohara K., Okamoto T., Asano A., Yoshino H. Miller Fisher syndrome associated with bulbar paralysis and elevation of antibodies against gangliosides. Pediatr Int. 1999 Dec;41(6):685–688. doi: 10.1046/j.1442-200x.1999.01135.x. [DOI] [PubMed] [Google Scholar]
  5. Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997 Jan 16;745(1-2):32–36. doi: 10.1016/s0006-8993(96)01123-7. [DOI] [PubMed] [Google Scholar]
  6. Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993 Oct;43(10):1911–1917. doi: 10.1212/wnl.43.10.1911. [DOI] [PubMed] [Google Scholar]
  7. Chiba A., Kusunoki S., Shimizu T., Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992 Jun;31(6):677–679. doi: 10.1002/ana.410310619. [DOI] [PubMed] [Google Scholar]
  8. FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956 Jul 12;255(2):57–65. doi: 10.1056/NEJM195607122550201. [DOI] [PubMed] [Google Scholar]
  9. Furiya Y., Murakami N., Kataoka H., Suzumura A., Takayanagi T. [A case of Fisher syndrome showing pharyngeal-cervical-brachial weakness with an elevation of anti-GQ 1 b and anti-GT 1 a antibodies]. Rinsho Shinkeigaku. 2000 Feb;40(2):166–169. [PubMed] [Google Scholar]
  10. Hashiguchi S., Ogasawara N., Yoshino H. [A case of Guillain-Barré syndrome with bulbar palsy and a high titer of anti-GT1a antibody]. Rinsho Shinkeigaku. 1997 Apr;37(4):331–333. [PubMed] [Google Scholar]
  11. Ilyas A. A., Cook S. D., Mithen F. A., Taki T., Kasama T., Handa S., Hamasaki H., Singhal B. S., Li S. C., Li Y. T. Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome. J Neuroimmunol. 1998 Mar 1;82(2):160–167. doi: 10.1016/s0165-5728(97)00197-5. [DOI] [PubMed] [Google Scholar]
  12. Kamakura K., Kaida K., Kusunoki S., Miyamoto N., Fukuda J., Motoyoshi K. Elevation in anti-GQ1b, anti-GT1a, and anti-GT1b IgG antibodies in postinfectious acute ataxic neuropathy with oropharyngeal palsy but without ophthalmoplegia. J Neurol. 2000 Jul;247(7):566–567. doi: 10.1007/s004150070160. [DOI] [PubMed] [Google Scholar]
  13. Kamata Y., Kozaki S., Sakaguchi G., Iwamori M., Nagai Y. Evidence for direct binding of Clostridium botulinum type E derivative toxin and its fragments to gangliosides and free fatty acids. Biochem Biophys Res Commun. 1986 Nov 14;140(3):1015–1019. doi: 10.1016/0006-291x(86)90736-9. [DOI] [PubMed] [Google Scholar]
  14. Kashihara K., Shiro Y., Koga M., Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):799–799. doi: 10.1136/jnnp.65.5.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kitamura M., Iwamori M., Nagai Y. Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim Biophys Acta. 1980 Mar 20;628(3):328–335. doi: 10.1016/0304-4165(80)90382-7. [DOI] [PubMed] [Google Scholar]
  16. Koga M., Tatsumoto M., Yuki N., Hirata K. Range of cross reactivity of anti-GM1 IgG antibody in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):123–124. doi: 10.1136/jnnp.71.1.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Koga M., Yuki N., Ariga T., Morimatsu M., Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J Neuroimmunol. 1998 Jun 1;86(1):74–79. doi: 10.1016/s0165-5728(98)00016-2. [DOI] [PubMed] [Google Scholar]
  18. Koga M., Yuki N., Hirata K. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom. J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):513–516. doi: 10.1136/jnnp.66.4.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Koga M., Yuki N., Tai T., Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology. 2001 Aug 28;57(4):686–691. doi: 10.1212/wnl.57.4.686. [DOI] [PubMed] [Google Scholar]
  20. Koga M., Yuki N., Takahashi M., Saito K., Hirata K. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes. J Neuroimmunol. 1998 Jan;81(1-2):138–143. doi: 10.1016/s0165-5728(97)00168-9. [DOI] [PubMed] [Google Scholar]
  21. MUNSAT T. L., BARNES J. E. RELATION OF MULTIPLE CRANIAL NERVE DYSFUNCTION TO THE GUILLAIN-BARR'E SYNDROME. J Neurol Neurosurg Psychiatry. 1965 Apr;28:115–120. doi: 10.1136/jnnp.28.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mizoguchi K., Hase A., Obi T., Matsuoka H., Takatsu M., Nishimura Y., Irie F., Seyama Y., Hirabayashi Y. Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1121–1123. doi: 10.1136/jnnp.57.9.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mizoguchi K., Uchiyama T., Obi T., Serizawa M., Nishimura Y., Irie F., Hirabayashi Y. Anti-GQ1b and anti-GT1a IgG antibodies in a patient with acute demyelinating polyradiculoneuropathy without ophthalmoplegia. J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):410–411. doi: 10.1136/jnnp.63.3.410a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nagano K., Koga M., Yuki N. [A case of pharyngeal-cervical-branchial variant of Guillain-Barré syndrome with IgG anti-GT1a antibody]. Rinsho Shinkeigaku. 1998 Apr;38(4):333–335. [PubMed] [Google Scholar]
  25. O'Leary C. P., Veitch J., Durward W. F., Thomas A. M., Rees J. H., Willison H. J. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry. 1996 Dec;61(6):649–651. doi: 10.1136/jnnp.61.6.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ropper A. H. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994 Jul;51(7):671–675. doi: 10.1001/archneur.1994.00540190051014. [DOI] [PubMed] [Google Scholar]
  27. Ropper A. H. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986 Nov;43(11):1150–1152. doi: 10.1001/archneur.1986.00520110044012. [DOI] [PubMed] [Google Scholar]
  28. Susuki K., Yuki N., Hirata K. Fine specificity of anti-GQ1b IgG and clinical features. J Neurol Sci. 2001 Mar 15;185(1):5–9. doi: 10.1016/s0022-510x(01)00464-6. [DOI] [PubMed] [Google Scholar]
  29. Ter Bruggen J. P., van der Meché F. G., de Jager A. E., Polman C. H. Ophthalmoplegic and lower cranial nerve variants merge into each other and into classical Guillain-Barré syndrome. Muscle Nerve. 1998 Feb;21(2):239–242. doi: 10.1002/(sici)1097-4598(199802)21:2<239::aid-mus13>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  30. Willison H. J., Kennedy P. G. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J Neuroimmunol. 1993 Jul;46(1-2):105–112. doi: 10.1016/0165-5728(93)90239-u. [DOI] [PubMed] [Google Scholar]
  31. Willison H. J., Veitch J., Paterson G., Kennedy P. G. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry. 1993 Feb;56(2):204–206. doi: 10.1136/jnnp.56.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yamashita H., Koga M., Morimatsu M., Yuki N. Polyneuritis cranialis related to anti-GT1 a IgG antibody. J Neurol. 2001 Jan;248(1):65–66. doi: 10.1007/s004150170273. [DOI] [PubMed] [Google Scholar]
  33. Yoshino H., Ariga T., Latov N., Miyatake T., Kushi Y., Kasama T., Handa S., Yu R. K. Fucosyl-GM1 in human sensory nervous tissue is a target antigen in patients with autoimmune neuropathies. J Neurochem. 1993 Aug;61(2):658–663. doi: 10.1111/j.1471-4159.1993.tb02170.x. [DOI] [PubMed] [Google Scholar]
  34. Yoshino H., Harukawa H., Asano A. IgG antiganglioside antibodies in Guillain-Barré syndrome with bulbar palsy. J Neuroimmunol. 2000 Jun 26;105(2):195–201. doi: 10.1016/s0165-5728(99)00280-5. [DOI] [PubMed] [Google Scholar]
  35. Yuki N., Handa S., Tai T., Takahashi M., Saito K., Tsujino Y., Taki T. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome. J Neurol Sci. 1995 May;130(1):112–116. doi: 10.1016/0022-510x(95)00045-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES